Concord Health Partners | James T. Olsen
page-template-default,page,page-id-819,tribe-no-js,ajax_fade,page_not_loaded,,select-child-theme-ver-1.0.0,select-theme-ver-3.1,menu-animation-underline,wpb-js-composer js-comp-ver-,vc_responsive

James T. Olsen

James T. Olsen

Founder & Managing Partner

James T. Olsen is the Founder & Managing Partner of Concord and a member of Concord’s Investment Committee.


Mr. Olsen is a healthcare sector specialist with 25 years of experience in healthcare private equity and investment banking. Prior to founding Concord in 2017, Mr. Olsen was a Managing Director & Group Head at Jefferies and Bank of America Merrill Lynch, where he began his career in 1996. Mr. Olsen has served as a trusted advisor and capital partner to a board universe of companies with over $25 billion in transactions across healthcare services, tech-enabled services, healthcare IT and medical technology.


Throughout his tenure in investment banking, Mr. Olsen served as a trusted advisor to leading health care organizations and executed several billion dollars in transactions across mergers & acquisitions and capital markets. He structured numerous strategic partnerships and developed innovative financing solutions across a range of debt and equity products. He has industry knowledge and transaction experience across a spectrum of healthcare sectors including healthcare services, healthcare information technology, medical devices and medical technology. Mr. Olsen has been a frequent speaker at healthcare industry conferences and seminars and has a broad network of relationships across the not-for-profit and for-profit healthcare sectors.
He currently serves on the Board of Directors for VitalTech Holdings, a Concord portfolio company, and Proton Therapy Partners, a specialty service provider that delivers proton therapy radiation oncology services.
Mr. Olsen received a B.S. in Physics from Loyola University Maryland and a M.S. in Physiology from the University of Maryland Graduate Program at the School of Medicine.